In a secondary analysis of HELIOS-B (486 of 654 ATTR-CM patients with KCCQ at baseline and 30 months), vutrisiran vs placebo was associated with more favourable changes in most KCCQ components (median +3.8 points), largest in physical limitation and quality-of-life items.
Secondary analysisn = 654
Hamatani et al. Effect of vutrisiran on components of health status in transthyretin amyloidosis with cardiomyopathy: the HELIOS-B study